Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q1 2014 · 10-Q
Revenue$1.05M$1.05M−0.6% vs Q1 2013 Net Income-$1.27M-$1.27MN/M vs Q1 2013 EPS Diluted-$0.06-$0.06N/M vs Q1 2013 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flow-$892,021N/M Free Cash Flowderived-$894,062— Margins · derivedGross margin-7.4%−5.4 pt vs Q1 2013
Operating margin-117.6%−11.3 pt vs Q1 2013
Net margin-121.0%−27.0 pt vs Q1 2013
ended Sep 30, 2013 · filed Nov 14, 2013 · 45 d after period end